GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impact BioMedical Inc (AMEX:IBO) » Definitions » Debt-to-Revenue

Impact BioMedical (Impact BioMedical) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2050. Start your Free Trial

What is Impact BioMedical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Impact BioMedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $12.79 Mil. Impact BioMedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Impact BioMedical's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.


Impact BioMedical Debt-to-Revenue Historical Data

The historical data trend for Impact BioMedical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impact BioMedical Debt-to-Revenue Chart

Impact BioMedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A 250.48 N/A N/A

Impact BioMedical Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Impact BioMedical's Debt-to-Revenue

For the Biotechnology subindustry, Impact BioMedical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Impact BioMedical's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impact BioMedical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Impact BioMedical's Debt-to-Revenue falls into.



Impact BioMedical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Impact BioMedical's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.074 + 0) / N/A
=N/A

Impact BioMedical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Impact BioMedical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Impact BioMedical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Impact BioMedical (Impact BioMedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
275 Wiregrass Parkway, West Henrietta, NY, USA, 14586
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Impact BioMedical (Impact BioMedical) Headlines

No Headlines